Targeting Folates by Carboxypeptidase G2: Potential Applications in Anticancer Therapy

Related Experiment Video

Updated: Aug 13, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

A. Krackhardt1, S. Schwartz, E. Thiel

  • 1Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin.

Onkologie
|July 7, 2001
PubMed

Insights

Carboxypeptidase G2 (CPG2) offers novel anticancer strategies by metabolizing methotrexate (MTX) and enabling targeted drug delivery. Further clinical studies are needed to fully establish its role in cancer therapy.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Carboxypeptidase G2 (CPG2) metabolizes folates and folate analogs, influencing folate metabolism pathways.
  • CPG2's interaction with methotrexate (MTX) is significant in anticancer therapy.
  • CPG2 has potential applications in managing MTX toxicity and enhancing drug delivery.

Purpose of the Study:

  • To explore the multifaceted roles of Carboxypeptidase G2 (CPG2) in anticancer therapy.
  • To evaluate CPG2 as a rescue agent for high-dose methotrexate (MTX) therapy and MTX intoxication.
  • To investigate CPG2's utility in antibody-directed enzyme prodrug therapy and combination treatments.

Main Methods:

  • Review of existing literature on CPG2's enzymatic activity and clinical applications.
  • Analysis of CPG2's effect on methotrexate (MTX) metabolism in preclinical and clinical settings.
  • Examination of CPG2's role in antibody-directed enzyme prodrug therapy and combination regimens.

Main Results:

  • CPG2 rapidly converts methotrexate (MTX) into less toxic metabolites, reducing MTX serum levels.
  • CPG2 acts as a potent rescue agent against MTX toxicity and intoxication.
  • CPG2 facilitates targeted delivery of cytotoxic agents in antibody-directed enzyme prodrug therapy.

Conclusions:

  • CPG2 demonstrates promising therapeutic potential in oncology, particularly in managing MTX-based chemotherapy.
  • CPG2 may enable MTX dose escalation and enhance the efficacy of targeted cancer therapies.
  • Further clinical research is essential to fully define CPG2's role and optimize its application in cancer treatment.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...